Investor Newsletter

Issue 03 2024

MicroPort®



MicroPort® Completes Enrollment in TARGET FIRST Trial with Firehawk™ Coronary Stent

MicroPort® is pleased to announce the completion of enrollment in TARGET FIRST trial.

Professor Giuseppe Tarantini, Principal Investigator of the study from the University Hospital of Padova, Italy, emphasized, "Our novel hypothesis seeks to optimize outcomes for acute myocardial infarction (AMI) patients by employing an innovative pharmaco-invasive strategy utilizing advanced stent technology coupled with comprehensive revascularization, thereby potentially reducing the necessity for dual antiplatelet therapy. We eagerly await the trial's findings."

The completion of patients' enrollment marks the end of a three-year enrollment period. The follow-up phase of these patients will last 12 months. TARGET FIRST trial results are expected in the first half of 2025.

MicroPort® CRM Announces the First Implantation of ALIZEA™ Bluetooth Pacemaker System in the United States

MicroPort® CRM, a pioneer in the field of Cardiac Rhythm Management, headquartered in France, announces the first implantation in the United States of the ALIZEA™ Bluetooth® pacemaker system, a combination of the ALIZEA™ pacemaker generator and VEGA™ pacing leads. The procedure was successfully completed by Doctor Jerry Floro at PIH Health Downey Hospital in Downey, California on Monday, March 18, 2024.

This latest pacemaker offering from MicroPort® CRM provides advanced heart rhythm management features and is equipped with Bluetooth® technology for comprehensive remote monitoring equivalent to an in-person follow-up. The full system consists of the ALIZEA™ implantable pacemaker used in combination with the VEGA™ active fixation pacing leads, SmartTouch XT™ tablet-based programmer, and SmartView Connect™ Bluetooth® mobile remote monitor.

Doctor Floro commented: “I believe that the remarkable longevity, advanced algorithms, and mobile remote monitoring offered in the Alizea™ pacemaker system, can play a crucial role in providing clinical benefit, safety, and convenience for patients.”

MicroPort

MicroPort® NeuroTech™ Completes the First Commercial Implantation of Tubridge™ Flow Diverter in Argentina

MicroPort® NeuroTech™ recently completed the first commercial implantation of Tubridge™ Flow Diverter (Tubridge™) in Argentina. The Tubridge™'s exceptional performance recieved high praise from the surgical team.

Tubridge™ offers comprehensive specifications, ranging from 2.5mm to 6.5mm in diameter and up to 45mm in length, addressing the majority of clinical aneurysm cases. These specifications mean that the Tubridge™ offers a superior option for larger or giant aneurysms. Moreover, braided with nitinol alloy wires, known for their superelasticity and ability to return to a predefined shape, Tubridge™ ensures excellent wall-apposition to tortuous intracranial vessels, facilitating endothelial cell growth and aneurysm healing.

From medical research to clinical application, Tubridge™ has redefined numerous pioneering standards within its category. Moving forward, MicroPort® NeuroTech™ remains dedicated to fostering deep collaborations with esteemed clinical experts worldwide, offering premium, comprehensive solutions to cerebrovascular patients worldwide.

MicroPort

MicroPort® MedBot™ JV's R-ONE® Vascular Intervention Robot Achieves Global Firsts in Bangladesh

Recently, R-ONE® Vascular Intervention Robot (R-ONE®), agented by Cathbot, a joint venture in China between MicroPort® MedBot™ and French company Robocath S.A.S, successfully performed several complex vascular interventional procedures at the National Institute of Cardiovascular Diseases (NICVD) in Bangladesh, marking several significant achievements in this field. As a result, R-ONE® became the global leading robot with the highest volume of complex multi-vessel and remote PCI procedures conducted.

R-ONE®'s key milestones include completing the world's first consecutive robot-assisted PCI remote procedure and the world's first remote robotic procedure to simultaneously implant two stents for complex coronary lesion.

Mr. Yu Liu, Executive Vice President and Chief Business Officer of MicroPort® MedBot™, remarked, "R-ONE® is equipped with several core technologies that extend and enhance the capabilities of the surgeon's hands, brain, and eyes. The recent series of high-difficulty coronary interventions performed in Bangladesh, which set multiple world records, exemplifies this advancement."

MicroPort

Toumai® Robot Performs First-Ever "World-Tour" of Robotic Tele-Surgery Operation Verification

From 3 to 4 February, the inaugural SRS Telesurgery Consensus Conference, hosted by the Society of Robotic Surgery (SRS), took place in Orlando, USA. Throughout this two-day event, nearly 200 attendees from multiple countries came together to discuss breakthroughs in tele-surgery, as well as to share clinical experiences and insights on performing these types of surgeries in the safest possible way.

MicroPort® MedBot™ participated in this conference and showcased the advanced capabilities of Toumai® Laparoscopic Surgical Robot (Toumai®), demonstrating its pivotal role in shaping the future of robotic surgery.

Dr. Chao He, President of MicroPort® MedBot™, was invited to deliver a keynote speech at the conference. He stated that the accomplishment of the first "world-tour" robotic tele-surgery verifications represents a further leap in tele-surgical technology. As of now, Toumai® has achieved a 100% success rate in over 100 cases of 5G tele-surgeries, helping make routine global tele-surgery possible. Its stability, reliability, and safety have been proven across diverse climates and natural settings.

MicroPort

Investor Newsletter

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
First Vice President of Board Secretary and Legal Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com